HK Stock Market Move | Biocytogen Pharmaceuticals-B(02315) rose by over 6% again, joining hands with SIHUAN PHARM to accelerate innovative drug development in areas such as weight loss by leveraging AI platform.

Biocytogen Pharmaceuticals-B (02315) rose by over 6%, with a 6.3% increase to HK$63.3 by the time of publication, with a turnover of HK$56.0117 million. On the news front, SIHUAN PHARM and Biocytogen Pharmaceuticals have officially signed a strategic cooperation agreement. The two parties will leverage Biocytogen Pharmaceuticals' leading fully human antibody development platform, combined with SIHUAN PHARM's extensive experience in drug development, production, and commercialization, to collaborate on and exchange innovative drug research and development in multiple disease areas including weight loss, to promote complementary advantages and resource synergy, and establish a long-term, stable cooperative relationship. The first collaborative project of this strategic cooperation will focus on the company's research on the next generation of innovative weight loss drugs. SIHUAN PHARM highly recognizes the technical strength of Biocytogen Pharmaceuticals' platform. In this collaboration, Biocytogen Pharmaceuticals will leverage its independently developed model animals and efficacy platforms, fully human antibody discovery platform, and AI-driven antibody drug development platform to provide strong support for the subsequent collaboration between the two parties. By integrating the capabilities of both parties in innovation research and industrial transformation, the collaboration is expected to further enhance the efficiency of innovative drug research and development.